Tyra Biosciences (TYRA) Net Income towards Common Stockholders (2020 - 2026)
Tyra Biosciences (TYRA) posted Net Income towards Common Stockholders of -$363.7 million for Q1 2026, down 968.75% on a QoQ basis from -$34.0 million in Q4 2025, and down 774.12% year-over-year from $54.0 million in Q1 2025.
Tyra Biosciences (TYRA) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends
Tyra Biosciences' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$363.7 million for Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 774.12% year-over-year to -$363.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$515.6 million (down 89.85% YoY) and the FY2025 annual result came in at -$306.6 million, down 154.92% from the prior year.
- Net Income towards Common Stockholders was -$363.7 million for Q1 2026 at Tyra Biosciences, down from -$34.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$13.0 million in Q4 2022 and bottomed at -$363.7 million in Q1 2026.
- A 5-year average of -$69.3 million and a median of -$41.9 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2025 — Net Income towards Common Stockholders soared 44.54% — and 2026, when it tumbled 774.12%.
- Tyra Biosciences' Net Income towards Common Stockholders stood at -$13.0 million in 2022, then tumbled by 76.13% to -$22.8 million in 2023, then retreated by 13.32% to -$25.9 million in 2024, then sank by 31.55% to -$34.0 million in 2025, then plunged by 968.75% to -$363.7 million in 2026.
- Business Quant data shows TYRA's Net Income towards Common Stockholders at -$363.7 million in Q1 2026, -$34.0 million in Q4 2025, and -$75.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | -0.68 |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Tyra Biosciences | 1.97 Bn | 1.97 Bn | - | -363.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -363.74 Mn |
| Dec 31, 2025 | -34.03 Mn |
| Sep 30, 2025 | -75.89 Mn |
| Jun 30, 2025 | -41.89 Mn |
| Mar 31, 2025 | -41.61 Mn |
| Dec 31, 2024 | -25.87 Mn |
| Sep 30, 2024 | -135.01 Mn |
| Jun 30, 2024 | -69.07 Mn |
| Mar 31, 2024 | -75.03 Mn |
| Dec 31, 2023 | -22.83 Mn |
| Sep 30, 2023 | -61.13 Mn |
| Jun 30, 2023 | -70.61 Mn |
| Mar 31, 2023 | -67.78 Mn |
| Dec 31, 2022 | -12.96 Mn |
| Sep 30, 2022 | -31.32 Mn |
| Jun 30, 2022 | -15.17 Mn |
| Mar 31, 2022 | -34.75 Mn |
| Dec 31, 2021 | -9.93 Mn |
| Sep 30, 2021 | -44.68 Mn |
| Jun 30, 2021 | -5.60 Mn |